Latest News

Sinovac Update on the Exchange of Rights for Common and Series B Preferred Shares



BEIJING–(BUSINESS WIRE)–Sinovac Biotech Ltd. (NASDAQ:SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, today issued an update on the Exchange of Rights for Common and Series B Preferred Shares announced February 22, 2019. On February 22, 2019, as announced by press release, the Sinovac Board of Directors effectuated an Exchange of Rights held by certain Sinovac’s shareholders for a combination of approximately 27.8 million Common Shares and approxim

Source link

Related posts

Electrical Stimulation Improves Reaction Time, Feels Natural

Newsemia

Medical Technologies Transforming the Future of Healthcare, 2018 Market Report – ResearchAndMarkets.com

Newsemia

Global Urethral Dilator Market 2019-2023 | Evolving Opportunities with BD and Cook | Technavio

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy

COVID-19

COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World